Carbamazepine (All indications)

ASD (Autism spectrum disorder): Risk

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9723
R34623		 Huber-Mollema (Carbamazepine), 2019 Autistic behavior (Social Emotional Questionnaire) (Completed by mothers) Clinical cutoff throughout pregnancy prospective cohort exposed to other treatment, sick Adjustment: No 0.26 [0.01;4.92] C 0/36   4/87 4 36
ref
S9975
R35858		 Bjørk (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 0.83 [0.29;2.38] C
excluded (control group) 		6/41   13/76 19 41
ref
S9976
R35859		 Bjørk (Carbamazepine) (Controls unexposed, disease free), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective unexposed, disease free excluded Adjustment: No 1.70 [0.72;4.05] C
excluded (control group) 		6/41   6,907/75,497 6,913 41
ref
S9977
R35860		 Bjørk (Carbamazepine) (Controls unexposed, sick), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: No 1.56 [0.60;4.03] C 6/41   27/272 33 41
ref
S9750
R34813		 Wood (Carbamazepine), 2015 Score 27-29 (CARS) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 0.78 [0.03;21.03] C 1/34   0/9 1 34
ref
Total 3 studies 1.27 [0.53;3.03] 38 111
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Huber-Mollema (Carbamazepine), 2019Huber-Mollema, 2019 1 0.26[0.01; 4.92]4369%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Bjørk (Carbamazepine) (Controls unexposed, sick), 2018Bjørk, 2018 2 1.56[0.60; 4.03]334184%ROB confusion: unclearROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Wood (Carbamazepine), 2015Wood, 2015 3 0.78[0.03; 21.03]1347%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: lowROB reporting: moderate Total (3 studies) I2 = 0% 1.27[0.53; 3.03]381110.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.27[0.53; 3.03]381110%NAHuber-Mollema (Carbamazepine), 2019 Bjørk (Carbamazepine) (Controls unexposed, sick), 2018 Wood (Carbamazepine), 2015 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.56[0.60; 4.03]3341 -NABjørk (Carbamazepine) (Controls unexposed, sick), 2018 1 exposed to other treatment, sickexposed to other treatment, sick 0.42[0.05; 3.81]5700%NAHuber-Mollema (Carbamazepine), 2019 Wood (Carbamazepine), 2015 2 Tags Adjustment   - No  - No 1.27[0.53; 3.03]381110%NAHuber-Mollema (Carbamazepine), 2019 Bjørk (Carbamazepine) (Controls unexposed, sick), 2018 Wood (Carbamazepine), 2015 3 All studiesAll studies 1.27[0.53; 3.03]381110%NAHuber-Mollema (Carbamazepine), 2019 Bjørk (Carbamazepine) (Controls unexposed, sick), 2018 Wood (Carbamazepine), 2015 30.15.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9975, 9976

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.70[0.72; 4.05]6,91341 -NABjørk (Carbamazepine) (Controls unexposed, disease free), 2018 1 unexposed, sick controlsunexposed, sick controls 1.56[0.60; 4.03]3341 -NABjørk (Carbamazepine) (Controls unexposed, sick), 2018 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.73[0.28; 1.89]241110%NAHuber-Mollema (Carbamazepine), 2019 Bjørk (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2018 Wood (Carbamazepine), 2015 30.510.01.0